Krystal Biotech, Inc. (KRYS)
331.61
+4.31
(+1.32%)
USD |
NASDAQ |
Oct 09, 16:00
331.58
-0.03
(-0.01%)
After-Hours: 20:00
Krystal Biotech Free Cash Flow (Quarterly) : 71.22M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.22M |
| March 31, 2026 | 73.23M |
| December 31, 2025 | 75.37M |
| September 30, 2025 | 37.96M |
| June 30, 2025 | 50.82M |
| March 31, 2025 | 24.76M |
| December 31, 2024 | 52.04M |
| September 30, 2024 | 57.81M |
| June 30, 2024 | -5.299M |
| March 31, 2024 | 14.63M |
| December 31, 2023 | -9.079M |
| September 30, 2023 | -23.01M |
| June 30, 2023 | -36.98M |
| March 31, 2023 | -31.54M |
| December 31, 2022 | -27.55M |
| September 30, 2022 | -33.74M |
| June 30, 2022 | -59.57M |
| March 31, 2022 | -32.68M |
| December 31, 2021 | -61.78M |
| September 30, 2021 | -28.25M |
| June 30, 2021 | -14.12M |
| Date | Value |
|---|---|
| March 31, 2021 | -12.13M |
| December 31, 2020 | -15.23M |
| September 30, 2020 | -10.95M |
| June 30, 2020 | -7.012M |
| March 31, 2020 | -7.735M |
| December 31, 2019 | -9.325M |
| September 30, 2019 | -5.418M |
| June 30, 2019 | -5.184M |
| March 31, 2019 | -5.185M |
| December 31, 2018 | -4.822M |
| September 30, 2018 | -2.772M |
| June 30, 2018 | -1.78M |
| March 31, 2018 | -2.369M |
| December 31, 2017 | -2.286M |
| September 30, 2017 | -1.11M |
| June 30, 2017 | -0.44M |
| March 31, 2017 | -0.264M |
| December 31, 2016 | -0.87M |
| September 30, 2016 | -0.312M |
| June 30, 2016 | -0.144M |
| March 31, 2016 | 0.00 |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 38.97M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Cytokinetics, Inc. | -164.17M |
| Exelixis, Inc. | 300.92M |
| Regeneron Pharmaceuticals, Inc. | 521.80M |